Is Adherence to Imatinib Mesylate Treatment among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?

Is Adherence to Imatinib Mesylate Treatment among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?

Show other versions (1)

Background Despite the revolutionary success of introducing tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), for treating chronic myeloid leukemia (CML), a substantial proportion of patients’ treatments fail. Aim This study investigates the correlation between patient adherence and...

Full description

Bibliographic Details
Main Authors: Nader I. Al-Dewik, Hisham M. Morsi, Muthanna M. Samara, Rola S. Ghasoub, Cinquea C. Gnanam, Subi K. Bhaskaran, Abdulqadir J. Nashwan, Rana M. Al-Jurf, Mohamed A. Ismail, Mohammed M. Alsharshani, Ali A. Alsayab, Tawfeg I. Ben-Omran, Rani B. Khatib, Mohamed A. Yassin
Format: Article
Language:English
Published: SAGE Publishing 2016-01-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.4137/CMO.S32822

Internet

https://doi.org/10.4137/CMO.S32822

Similar Items